GliaPharm

Geneva, Switzerland· Est. 2016

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $9.2M

Overview

GliaPharm is a private, preclinical-stage biotech leveraging decades of glial cell research to develop neuroprotective therapies. The company has established the GliaX technology platform to discover and develop small molecules targeting glial cells, with an initial focus on Alzheimer's disease, epilepsy, and ALS. Backed by a strong scientific foundation from co-founder Prof. Pierre Magistretti and led by an experienced executive team, the company has secured non-dilutive funding, including a $4.2M investment from the Alzheimer's Drug Discovery Foundation (ADDF) in 2023. GliaPharm represents a novel approach in neurology by targeting non-neuronal cells, aiming to address high-unmet-need conditions with limited treatment options.

Alzheimer's DiseaseEpilepsyAmyotrophic Lateral Sclerosis (ALS)Neurological Disorders

Technology Platform

GliaX™ - A proprietary platform decoding glial cell research to discover drugs targeting glia-mediated pathways for neuroprotection and cognitive maintenance. It utilizes advanced models like brain organoids for target validation and compound screening.

Funding History

Total raised:$9.2M

Series A$8MVesalius BiocapitalApr 15, 2022

Seed$1.2MZurich Cantonal BankNov 15, 2019

Opportunities

The company is pioneering a novel glia-centric approach in neurology, targeting high-unmet-need diseases like Alzheimer's and ALS where current therapies are inadequate.

Success in one indication could validate the platform for broader application across multiple neurological and psychiatric disorders.

Strategic non-dilutive funding from expert foundations like ADDF de-risks early development and validates the scientific thesis.

Risk Factors

The core scientific risk is high, as translating novel glial biology into safe and effective human therapeutics is unproven and complex.

As a preclinical, pre-revenue company, GliaPharm faces significant funding risk and is reliant on raising capital to advance its programs.

It also operates in a competitive landscape where larger players may eventually target similar biology.

Competitive Landscape

GliaPharm operates in a niche but emerging competitive space focused on glial and non-neuronal targets in neurology. It faces competition from both large pharma companies (e.g., Biogen, Roche) exploring neuroinflammation and smaller biotechs targeting specific glial pathways. Its key differentiator is its deep foundational science from Prof. Magistretti and its integrated GliaX platform dedicated solely to this target class.